AKODIO

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 17 Mar 2025 filing date already counts against anyone who files later.

Record

Serial number

99087526

Mark type

Stylized text

Filed

17 Mar 2025

Published for opposition

21 Apr 2026

Attorney of record

Brandon P. Leahy

Goods and services

• Class 005 — Pharmaceuticals: Monoclonal antibodies and drug conjugates for the treatment of multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy; biological products, namely, monoclonal antibodies for experimental purposes as part of medical treatment for multiple Sclerosis, Alzheimer disease, stroke, traumatic brain injury, long COVID, postoperative cognitive decline, brain B-cell lymphoma, small vessel disease (CADACIL), adrenoleukodystrophy
• Class 010 — Medical apparatus: Medical probes; probes for medical imaging, namely, fluorescent and PET probes; medical devices for neuroimaging, neuro-diagnostics and neuro-monitoring

Owner

• Akodio Therapeutics, Inc., San Francisco, CA, US

Prosecution history

• 26 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 25 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 25 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 25 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 17 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 17 Mar 2026 — NON-FINAL ACTION E-MAILED
• 17 Mar 2026 — NON-FINAL ACTION WRITTEN
• 20 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 20 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 20 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 24 Nov 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 24 Nov 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 22 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 22 Aug 2025 — NON-FINAL ACTION E-MAILED
• 22 Aug 2025 — NON-FINAL ACTION WRITTEN